Press releases and news

Stay informed with our latest news and press releases

Staining of E cadherin-Beta catenin interaction in TMA

New kits for Leica BOND RX/RXm with fluorescent readout

Leica Biosystems and Navinci collaborate to automate in situ proximity ligation assays, now with fluorescent readout.

jenny fade crop

Jenny Sundqvist appointed CEO of Navinci

Navinci’s Board of Directors is pleased to announce the appointment of Jenny Sundqvist as the new Chief Executive Officer, effective December 1, 2024.

new partnerships navinci x precision for medicine gradient

Precision for Medicine and Navinci Announce Strategic Partnership

A partnership announced between Precision for Medicine and Navinci to offer isPLA as part of Precision for Medicine’s CRO services.

Mesothelin and Mucin interaction in ovary fluorescence readout

Navinci announces stepping down of CEO, Robert Gunnarsson

Navinci announces CEO Robert Gunnarsson’s resignation, with Agata Zieba-Wicher as interim leader while the board searches for a permanent successor.

E-cadherin-Beta-catenin-interaction-healthy-colon-NaveniFlex-Tissue_ header

Partnership announced between Canopy Biosciences and Navinci

A partnership announced between Canopy Biosciences and Navinci to offer isPLA as part of Canopy’s CRO services.

Sopana Leife-Navinci

Navinci strengthens leadership with new Director of Operations

Navinci Diagnostics AB announces the appointment of Sopana Leife as new Director of Operations, effective September 2nd 2024.

Andrea Ballagi Navinci

Andrea Ballagi joins Navinci Board of Directors

Navinci are pleased to announce the appointment of Andrea Ballagi to the board, bringing further leadership expertise to the Company.

Leica Biosystems and Navinci Press Release

Leica Biosystems and Navinci Partner to Accelerate Cancer Research

Leica Biosystems, a global leader in anatomic pathology, and Navinci, announce a strategic collaboration to drive innovation in cancer patient care.

Navincihousewarmingparty-14

Navinci Housewarming Party

Last Friday (May 3), Navinci had the absolute pleasure of hosting a housewarming party to celebrate the grand opening of our new office, with a fantastic turnout.

Navinci homepage-illuminating function in spatial proteomics

Navinci Presents Cutting-Edge Cancer Research at AACR24

Navinci will present our latest data on the annual meeting American Association for Cancer Research 2024 (AACR), in San Diego, US. Come by our booth and meet the team.

new office bw

Navinci expands into new facilities

Navinci celebrates a milestone, relocating to Uppsala Science Park, bolstering R&D capabilities. The move reflects continued growth and commitment to pioneering spatial proteomics.

Navinci CD8/MCH-I

Product launch: Naveni® CD8/MHC-I  kit

Introducing Naveni® CD8/MHC-I in situ assay kit, revealing immune response intricacies. Revolutionize cancer treatment with nuanced insights, advancing precision medicine.

New strategic partnership between 2B Scientific and Navinci

Navinci and 2BScientific announce a strategic partnership

Navinci partners with 2BScientific, UK’s premier life sciences distributor, expanding reach for spatial proteomics assays, benefiting researchers with innovative solutions in the UK.

Navinci and Milner logos

Navinci joins Milner Therapeutics Institute Affiliated Company scheme

Navinci joins the Milner Therapeutics Institute Affiliated Company scheme, fostering collaboration among academic, pharmaceutical, and biotech partners to advance research and innovation.

Navinci- illuminating function in spatial proteomics

Assay database alert! E-cadherin/β-catenin added

Explore our assay database’s new addition: E-cadherin/β-catenin interactions’ impact on cell adhesion and cancer progression, illuminating critical biological processes.

IMG_9322 bw

Navinci and Vector Labs announce strategic collaboration

Vector Laboratories and Navinci Diagnostics partner to pioneer biomarker discovery tools, enabling specific protein glycosylation detection in tissue samples, revolutionizing glycoproteomic research.

Cox1GM130_merge

Exciting news: Explore our dynamic assay database!

Introducing our newest feature – the assay database, with demonstrated assays and protocols for targeted protein-protein interactions and specific protein detection!

microscopic image of protein interactions

Navinci Diagnostics has partnered with Shanghai Universal Biotech

Navinci Diagnostics has entered into a partnership with Shanghai Universal Biotech, becoming our exclusive distributor for the Chinese market.

microscopic picture of protein interactions

Navinci and Research Instruments announce a strategic partnership

Navinci have reached a distribution partnership with leading supplier of cutting-edge research and life science tools Everlife-Research Instruments.

PPI PD1 PDL1 Atto647N

Exciting Times in the World of Proteomics!

Thermo Fisher Scientific’s remarkable $3.1 billion acquisition of Olink Proteomics is a testament to the incredible technology that forms the foundation of Olink Proteomics.

NavenFlex Tissue GR_Atto Colon Beta-Cat_E-Cad interaction

Expanding our reach – new distribution partnership in Italy

Navinci is excited to announce a distribution collaboration with EuroClone, a strategic move aimed at advancing our global sales expansion efforts.

PDGFRb-pTyr

New Research Unveils p53 Aggregates’ Vital Role in Ovarian Cancer Prognosis and Treatment Strategies

The authors used the NaveniFlex™ assay and we are proud our research tools proved to be of great importance in ovarian cancer research.

Naveni TriFlex Histone H3 Lamin B protein detection and interaction

CICON-23, 20-23 September, Milan Italy

Come and meet Navinci’s Doroteya Raykova and Inge Cyrén at the CICON-23 Conference in Milan, Italy, 20-23 September.

Expanding Your Options with NaveniLink™

Would you like to perform a proximity ligation assay using your own primary antibodies? Our NaveniLink conjugation kit allows you to do just that.

Product Advancement: NaveniFlex™ Cell

This cutting-edge kit is meticulously fine-tuned for in situ cell analysis and delivers enhanced signal strength, a shorter protocol including a separate protocol for 96-well plates.

NaveniFlex in Autophagy publication

Naveni® technology has been referenced in a publication describing novel insights into the process of lysosomal degradation of mitochondria.

Cayman and Navinci Announce Strategic Partnership

Cayman and Navinci Announce Strategic Partnership Expanding Access to Next-Generation Tools for Spatial Proteomics Ann Arbor, MI – 07/05/2023 – Global life sciences supplier Cayman Chemical (Cayman) announced today a strategic partnership with Navinci Diagnostics (Navinci), a Swedish biotechnology company developing innovative tools for spatial proteomics. This partnership expands access to Navinci’s portfolio of proximity…

Illuminate PD1/PD-L1 interactions – new product out!

Illuminate PD1/PD-L1 interactions – new product out! 23-06-12 Uppsala Navinci expands its portfolio to unravel PD1 signaling, introducing the fluorescent assay, Naveni™ PD1/PD-L1 Atto 647N. With Naveni™ PD1/PD-L1 Atto 647N, you can now achieve a comprehensive visualization of the tumor microenvironment through co-staining. Illuminate PD1/PD-L1 interactions like never before and gain a deeper understanding of…

Navinci at EACR 2023 Congress – Unleashing Innovation

Navinci at EACR 2023 Congress – Unleashing Innovation 23-06-12 Uppsala A new product will be unveiled at the EACR Congress, where the Navinci team, consisting of Ida Hansson (Scientific Sales Specialist), Eva Auieong (Laboratory Manager), Hampus Elofsson (Senior Scientist), and Daniel Ekman (Customer Support Manager), will showcase our latest developments at booth 79. Make sure…

Spatial Biology US – latest innovations in spatial research & technologies

Navinci is a silver sponsor at Spatial Biology US 23-06-08 Uppsala Don’t miss the opportunity to meet our team consisting of Inge Cyrén (Area Manager North America), Subham Basu (CBO), and Doroteya Raykova (Applications Scientist). Doroteya Raykova will present our latest advancements in spatial proteomics  (June 8th 12:40). She will explore the fascinating world of protein-protein interactions (PPIs) and shed light…

Spatial Biology UK – latest innovations in spatial research & technologies

Spatial Biology UK – latest innovations in spatial research & technologies 23-04-21 Uppsala Navinci is joining Spatial Biology UK an Oxford Global event in London April 25-26th , a 2-day event that explores spatial research: from the application of spatial technologies in biology through to topical updates from spatial genomics, transcriptomics, metabolomics and spatial bioinformatics.…

Navinci Diagnostics announces the appointment of Dr Subham Basu as new Chief Business Officer

Press release Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the appointment of Dr Subham Basu as new Chief Business Officer, effective April 11th 2023. Dr Subham Basu will join Navinci to lead the organizational build-up and international commercialization of the unique Navinci product portfolio for Spatial…

Navinci at AACR – new research data and product developments

Navinci at AACR – new research data and product developments 31-03-2023 Uppsala Navinci will attend AACR on April 14-19th in Orlando, US. We will showcase our latest product designs and tell you what is new in protein-protein interaction technology. You can find us in the exhibition hall (booth 1771) and at the scientific sessions with four poster presentations including…

Exhibition at SciLifeLab: March 30th, between 09.00-15.00

Exhibition at SciLifeLab 23-03-29 Uppsala Are you in Uppsala? Stop by BMC, Navet, and the Life Science exhibition! We will be there on March 30th, between 09.00-15.00, this is a chance to receive information and updates from us and 9 others of the leading life science companies in Sweden (and to get some goodies). SciLifeLab…

Seminar: How to detect protein-protein interactions – Latest innovations in Proximity Ligation Technology

Seminar: How to detect protein-protein interactions – Latest innovations in Proximity Ligation Technology March 15th, Biomedicum D1012 Karolinska Institutet, Solna Sweden We’re excited to invite you to our in-person seminar! In this session, you will learn how to visualize protein interplay in situ and how the latest Naveni proximity ligation technologies are pioneering molecular biology research. …

Navinci Diagnostics AB appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board

Navinci Diagnostics AB appoints Eva Pisa as chairman, further strengthens the leadership team, and establishes a Scientific Advisory Board In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr.…

An eye-opening solution for tissue samples – launch of NaveniFlex™ Tissue

An eye-opening solution for tissue samples – launch of NaveniFlex™ Tissue Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced Naveni™ proximity ligation technology we developed for NaveniFlex™ Tissue kits are tailor-made to overcome common background challenges in tissue samples. The kits are optimized for tissue samples to deliver…

Discover the secret life of proteins – concurrently visualize two proteins in a free and complex state

Discover the secret life of proteins – simultaneously visualize two proteins in a free and complex state Ever wish there were a way to take a snapshot of two proteins as they interact or remain unbound? Now, the door is open to study protein interplay and functional states while keeping the structural integrity of cells.…

Here to make a difference – the first PD1/PD-L1 interaction assay

Here to make a difference – the first PD1/PD-L1 interaction assay Immune checkpoint inhibitors have revolutionized cancer immunotherapy, and more than 3000 anti-PD1/PD-L1 therapies are currently in clinical trials. The leading technology used to determine whether a patient is likely to benefit from PD1/PD-L1 immunotherapy is PD-L1 immunohistochemistry. However, this test doesn’t reveal whether the…

Low signal and multiple non-specific bands in your Western Blot? Learn how to surpass the problems

Low signal and multiple non-specific bands in your Western Blot? Learn how the authors of a recently published paper surpassed the problems and created a sensitive and specific Western Blot with Naveni™ Proximity Ligation Technology. Dr. Athanasios Alexandris is a postdoc at the department of Pathology at Johns Hopkins in the lab of Professor Vassilis…

Navinci Diagnostics AB announces closing of SEK 90M Series A financing, led by Segulah Medical Acceleration with support from existing shareholders

Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of a SEK 90 million financing round. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.…

Naveni pY PD1 – new in situ kit for detection of phosphorylated PD1!

Navinci has developed several in situ Proximity Ligation Assays, providing deep biological knowledge about the signaling pathways of PD1 and PD-L1. The first assay available to order is: Naveni pY PD1 (phosphorylated PD1) PD1 PD-L1 signaling has proven significant in cancer progression, and therapies with immune checkpoint inhibitors have revolutionized cancer treatment efficacy. Despite the…

Coming soon! Naveni PD1/PD-L1 and Naveni pY PD1

COMING SOON Naveni PD1/PD-L1 Protein-protein interaction (PPI): Proximity Ligation assay for detection of PD1/PD-L1 interaction Naveni pY PD1 Protein post-translational modifications (PTM): Proximity Ligation assay for detection of phosphorylated PD1 Contact us

New publication out!

New publication out! Wåhlén et al. have just published the article: Differential impact of lipid raft depletion on platelet-derived growth factor (PDGF)-induced ERK1/2 MAP-kinase, SRC and AKT signaling – ScienceDirect In the study, they analyzed the co-localization of PDGFR-β and GRB2, PI3K or clathrin, using our Naveni Proximity Ligation Technology. Citation: “For this purpose, NaveniFlex…

Launch News – pY VEGFR2. Navinci is expanding the Naveni PTM product line.

Quantify phospho-VEGFR2 in situ Navinci is expanding the Naveni PTM product line! Quantify phosphorylated VEGFR2 with outstanding signal-to-noise ratio. Receptor tyrosine kinases (RTKs) are involved in cellular processes and altered phosphorylation states may lead to disturbed signaling pathways, tumor progression, and cancer. Specific tools for quantifying phosphorylation of RTKs in situ have been requested for…

Launch News – NaveniBright kits. Proximity Ligation Assay now with bright-field read out.

LAUNCH NEWS Navinci is taking the next step to meet the needs of the pathology field. NaveniBright is a new product line with chromogenic readout. The in situ kits are based on our Naveni Proximity Ligation Technology and significantly enhance the chromogenic signal, providing you with stronger and more accurate staining. The assay gives you detailed…

Navinci Diagnostics partners with Ozyme for the distribution of Naveni products in France.

Navinci Diagnostics partners with Ozyme for the distribution of Naveni products in France. Ozyme is a highly skilled partner with deep insight into immunoassays and antibody-related research. Ozyme will make it possible for our French customers to interact with a local distributor with great knowledge within the biotech field. We look forward to working closely with Ozyme;…

Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET

Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET We are now launching target-specific Naveni in situ proximity ligation assays for phosphorylated receptor tyrosine kinases EGFR, HER2, PDGFR-beta and MET. The assays are based on dual epitope recognition by two primary Navenibodies, that generate an amplified signal when bound in close proximity. This…

Navinci and SciLife enters collaboration: Naveni in situ Proximity Ligation Assay technique will be provided by the SciLifeLab unit Affinity Proteomics Uppsala.

”We are delighted to partner with SciLifeLab and the Affinity Proteomics unit in Uppsala, as this allows the NaveniTM in situ proximity ligation assay technology to support the mission of SciLifeLab to enable life science research in Sweden to provide access to the latest key technologies. This collaboration will significantly benefit our academic customers that…

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells This innovative test from OncoLab (Austria) identifies cancer cells via p53 prions and is based on the proprietary proximity ligation technology from Navinci. The test kits can be used with tissues, cells, and…

Navinci Diagnostics AB and Lucerna-Chem AG have entered a distribution agreement for the Swiss market

Uppsala and Luzern, September 2021. Navinci Diagnostics AB and Lucerna-Chem AG have entered a distribution agreement for the Swiss market. ”Switzerland is an important market for Navinci and Lucerna-Chem is an excellent organization for us to partner with as they have a strong presence in the region, customer base, and network. We much look…

Proximity ligation: A revolutionary protein detection technology – Made in Uppsala

Cellular processes can only be understood as the dynamic interplay of molecules. This means that we need accurate techniques to monitor interactions of endogenous proteins directly in individual cells and tissues, to reveal the cellular and molecular architecture and its responses to disturbances. Protein detection with higher sensitivity and specificity is a constant need in…

Shows the specific localization of ACE 2 with NaveniFlex

The importance of specific protein detection in ACE2 localization studies

Correct localization of proteins is critical for both the understanding and treatment of many diseases. High specificity immunoassays are of particular value for precision diagnostics use and in large-scale therapeutics development. The quality of these in situ protein detection assays depends mainly on the antibodies’ specificity against the target. Many commercial antibodies have low specificity,…

Detect phosphorylation with NaveniFlex proximity ligation

Protein phosphorylation has been the target of many drugs, both approved and under development, as well as diagnostics. Phosphorylation status lies beyond the capability of transcriptomics or genomics and is commonly addressed with antibody-based techniques. Most commercially available phospho-antibodies show a moderate-to-high lack of both specificity and sensitivity in immunostainings. It results in generating false-positive…

Staining of E cadherin-Beta catenin interaction in TMA

New kits for Leica BOND RX/RXm with fluorescent readout

Leica Biosystems and Navinci collaborate to automate in situ proximity ligation assays, now with fluorescent readout.

jenny fade crop

Jenny Sundqvist appointed CEO of Navinci

Navinci’s Board of Directors is pleased to announce the appointment of Jenny Sundqvist as the new Chief Executive Officer, effective December 1, 2024.

new partnerships navinci x precision for medicine gradient

Precision for Medicine and Navinci Announce Strategic Partnership

A partnership announced between Precision for Medicine and Navinci to offer isPLA as part of Precision for Medicine’s CRO services.

Mesothelin and Mucin interaction in ovary fluorescence readout

Navinci announces stepping down of CEO, Robert Gunnarsson

Navinci announces CEO Robert Gunnarsson’s resignation, with Agata Zieba-Wicher as interim leader while the board searches for a permanent successor.

E-cadherin-Beta-catenin-interaction-healthy-colon-NaveniFlex-Tissue_ header

Partnership announced between Canopy Biosciences and Navinci

A partnership announced between Canopy Biosciences and Navinci to offer isPLA as part of Canopy’s CRO services.

Sopana Leife-Navinci

Navinci strengthens leadership with new Director of Operations

Navinci Diagnostics AB announces the appointment of Sopana Leife as new Director of Operations, effective September 2nd 2024.